Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs Lithium Americas Corp (LAC) Price & Performance

AbCellera Biologics IncTrade
Lithium Americas CorpTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs Lithium Americas Corp — how do they compare? AbCellera Biologics Inc trades at $9.05 (market cap $2.85B), while Lithium Americas Corp trades at $3.26 (market cap $1.18B). The key difference: AbCellera Biologics Inc is far larger — about 2.4× Lithium Americas Corp's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Lithium Americas Corp nearer its low. Which is the better fit depends on your goals.

ABCLLAC
Market Cap
$2.85B$1.18B
Sector
HealthBasic Materials
52-Week High
$9.76$10.05
52-Week Low
$2.78$2.71
Enterprise Value
$2.45B$1.30B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.

The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.

Lithium Americas Corp

Lithium Americas (LAC) trades at $3.23, up 6.95% today, but remains in a bearish technical trend with negative profitability metrics. The company reported a net loss of $122.09 million for 2025 and continues to burn cash from operations. Recent news highlights $175 million financing for Thacker Pass construction, providing balance sheet support amid ongoing capital expenditures exceeding $900 million annually.

While analyst consensus leans positive with no sell ratings, significant execution risks persist as LAC navigates peak construction phase. The stock faces headwinds from negative ROE (-11.35%) and cash burn, though strategic positioning in lithium development offers long-term potential if project timelines and funding are successfully managed.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About Lithium Americas Corp

Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.

Read more on LAC